STOCKHOLM, SWEDEN / RankWire.AI / – On October 5, the Nobel Assembly at Karolinska Institutet announced that Karl Deisseroth, Peter Hegemann and Georg Nagel are recipients of the 2026 Nobel Prize in Physiology or Medicine for their pioneering work establishing the field of optogenetics. Their discoveries provided scientists with an exact method to manipulate specific nerve cells using light, a technique that now plays a fundamental role in research related to brain circuitry, behavior, memory, and disease. It has become one of the most significant tools in neuroscience experiments.
Hegemann and Nagel elucidated the function of channelrhodopsin in the green alga Chlamydomonas. This protein creates a light-responsive channel within the cell membrane, where blue light opens the channel, allowing charged ions to pass through, which can initiate electrical activity inside the cell. Their experiments demonstrated that channelrhodopsin could be expressed in other cell types to make them respond to light, laying the foundation for controlling cell activity with light flashes.
Deisseroth subsequently adapted this discovery for use in neuroscience. In 2005, he demonstrated that channelrhodopsin could induce rat nerve cells to respond to blue light, showing that light could trigger electrical signals in targeted neurons. Later studies confirmed that this technique also works in living animals, transforming optogenetics into a practical tool to investigate how specific brain circuits influence activity and behavior. This approach provides researchers with far greater precision than many earlier methods.
Light-based control revolutionizes brain research
Optogenetics combines genetic targeting with light-sensitive proteins, enabling researchers to activate or silence specific groups of nerve cells. This precise control assists scientists in exploring how distinct circuits contribute to movement, learning, emotion, and memory. The Nobel Assembly stated that this technique has transformed studies of living brains, allowing labs to link activity in targeted cells with observable behavioral changes, without simultaneously stimulating broad tissue areas.
Currently, optogenetics is widely applied in research on Parkinson’s disease, epilepsy, depression, addiction, and other neurological disorders. It is also being explored for addressing severe vision loss, with experimental methods aiming to restore light sensitivity in retinal cells. These medical applications are still under development and are not yet standard treatments. Nonetheless, the technique’s primary role remains in research, where it facilitates detailed examination of complex biological systems, extending its influence beyond neuroscience into various fields of cell biology.
Three scientists share the Nobel in medicine
Deisseroth is affiliated with Stanford University and the Howard Hughes Medical Institute in the United States. Hegemann is based at Humboldt University of Berlin, while Nagel conducts research at the University of Würzburg in Germany. The trio will split 12 million Swedish kronor for their contributions. Their work represents distinct but interconnected steps in the evolution of modern optogenetics—spanning the discovery of light-sensitive proteins, their characterization, and their application for nerve cell control.
This award highlights a scientific journey that started with a simple organism and significantly transformed contemporary brain research. Channelrhodopsin served as the molecular switch enabling precise optical control. Deisseroth’s efforts helped integrate this switch into nerve cells and living brains. Today, optogenetics is utilized across neuroscience and other biological disciplines. The laureates will receive their Nobel medals and diplomas in Stockholm on December 10, marking the anniversary of Alfred Nobel’s death, following longstanding Nobel tradition.